Medications

Combination therapy can delay resistance of lung cancer cells

A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...

Oncology & Cancer

Using AI to trace the origins of metastatic cancer cells

A large team of cancer researchers affiliated with several institutions in China, working with a pair of colleagues in the U.S., has found that artificial intelligence applications can be used to trace the origins of metastatic ...